Clinical trial
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White…
NCT00244946 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00244946 |
|---|---|
| Title | Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | Immune Consolidation With Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphomas |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | therapeutic autologous lymphocytes, carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation (PBSCT) |
| Enrollment | 15 |
| Start date | Mar 1, 2004 |
| Primary completion | Jan 1, 2010 |
| Completion | Mar 1, 2013 |
| First posted | Oct 27, 2005 |
| Last update posted | Mar 26, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: